Ozempic 'Significantly' Lowered 'Alcohol Craving' in First Clinical Trial, with Those Taking the Drug Drinking 40% Less

• The new study (first clinical examination of this kind) showed that GLP-1 agonist semaglutide-known by the Oskempic-can help reduce not only craving for alcohol, but also the amount of alcohol consumed when someone on the medicine drinks a drink
• The study revealed “significantly reduced weekly craving for alcohol” – and also showed a promise in helping to suppress the desire for cigarettes
• With 48 participants for nine weeks, researchers admit that the study is limited, “health implications could be significant”

It was theorized that Orempic could potentially help in the disorders of the abuse of the substance because of the way it operates in the brain. Now the first clinical study of a potential relationship suggests that the drug can truly help in the disorder of alcohol use.

Drug-Robno brand for GLP-1 agonist semaglutide- “significantly reduced the weekly craving for alcohol,” said the study published on Wednesday, February 12, in Magazine psychiatry American Medical Association.

In May 2024. Novo Nordisk, Orempic manufacturer, announced that he would study the influence of the drug on the craving for alcohol, citing “a significant dissatisfied medical need in a liver disease associated with alcohol, and the first line of treatment is in a state of life intervention to life to abstain from your life drinking alcohol. ”

Oskempic picture.

Steve Christ/Corbis/Corbis/Getty

The study consisted of 48 participants (34 women, 14 men), and half of the participants received a weekly semaglutide injection week with low doses, while the other half received placebo. The participants of the study are located in a casual environment with a stocked tape.

“They drank freely as much as they wanted, to the restrictions we set,” said Dr. Christian Hendershot, director of clinical research at the USC Institute of Addiction and the leading author of the study, for CNN. During a nine -week experiment, not only were alcohol reduced, but when they drank alcohol on the medicine, they drank less. In addition, the subgroup saw “more relative reduction of cigarettes a day.”

Stars that spoke of Orempic – and what they said

“We were hoping to see a reduction in drinking and craving,” Hendershot told the Study socket, which saw those on semaglutide that they drink 40% less alcohol than those on the placebo. “What I didn’t expect was that the size of the effects looked pretty good … compared to other drugs disorders in the use of alcohol.”

Orempic and others in their class (semaglutides are also sold under the Wegovy and Mounjaro brands) work in the brain to influence satiety. Although the FDA has approved the ground for people with type 2 diabetes, not necessarily for weight loss, it has become trendy help with weight loss.

However, those who take Oskempic reported other advantages, such as reduced risks of heart disease, kidney disease and Alzheimer’s disease, as well as increased fertility and reduction in alcohol.

Stock painting a bottle with alcoholic beverages.

Tetra Pictures/Getty

Although some of these advantages are the result of weight loss, the way semaglutide affects the reduction of craving, indeed, may be associated with addiction.

A study in a journal Addiction They found that people dependent on alcohol that took the ground or similar medicines had a 50% lower stock of stock on alcohol than those who did not. And people with the disorder of the use of opioids that were taking medication had a 40% lower overdose rate of opioids.

1 of 8 adults in the USA have taken the ground or similar medicines, according to a new study

Although this study admits that it is limited by “modest sample size and short-term duration of treatment”, she notes that if GLP-1 drugs are shown to help use alcohol and smoking, “health consequences could be significant.”

Never miss the story -son for a daily newsletter of people to be up to date with the best of what people can offer, from news of glorious to convincing stories of human interest.

As the study says, “the use of alcohol and cigarettes (together with obesity) lead the causes of mortality and prevention of cancer death, making individuals who smoke and drink very much – including those with overweight or obesity – priority population.”

“These findings provide initial perspective evidence that low-dose semaglutide can reduce craving and some drinking results,” researchers said: “Justification for major clinical trials for assessing GLP-1ra for alcohol use disorder.”

Categories: Trends
Source: HIS Education